| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/18/2007 | CA2628498A1 Viscoelastic compositions comprising polycationic quaternary ammonium compounds |
| 05/18/2007 | CA2628441A1 Compounds for modulating trpv3 function |
| 05/18/2007 | CA2628413A1 Prostaglandins and analogues as agents for lowering intraocular pressure |
| 05/18/2007 | CA2628403A1 Rifamycin analogs and uses thereof |
| 05/18/2007 | CA2628305A1 Jelly composition |
| 05/18/2007 | CA2628265A1 The use of compositions comprising ketoacids and amino acids for increasing muscle mass and muscle performance |
| 05/18/2007 | CA2628260A1 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof |
| 05/18/2007 | CA2628120A1 Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis |
| 05/18/2007 | CA2628110A1 Methods of sensitizing cancer to therapy-induced cytotoxicity |
| 05/18/2007 | CA2628093A1 Antisense oligonucleotide analog compounds targeting proprocessed ctla-4 mrna |
| 05/18/2007 | CA2628039A1 Novel pyridopyrazines and their use as modulators of kinases |
| 05/18/2007 | CA2627942A1 Use of clodronic acid for the treating podotrochlosis |
| 05/18/2007 | CA2627923A1 Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| 05/18/2007 | CA2627857A1 Aminopyrimidines useful as kinase inhibitors |
| 05/18/2007 | CA2627839A1 Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| 05/18/2007 | CA2627830A1 Aminopyrimidines useful as kinase inhibitors |
| 05/18/2007 | CA2627808A1 Aminopyrimidines useful as kinase inhibitors |
| 05/18/2007 | CA2627726A1 Aerosolformulation for inhalation |
| 05/18/2007 | CA2627719A1 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| 05/18/2007 | CA2627588A1 Pharmaceutical combination |
| 05/18/2007 | CA2627426A1 Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa |
| 05/18/2007 | CA2627363A1 Compounds for the treatment of insulin resistance syndrome and diabetes |
| 05/18/2007 | CA2627358A1 Heterocyclic modulators of atp-binding cassette transporters |
| 05/18/2007 | CA2627353A1 Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors |
| 05/18/2007 | CA2627352A1 Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors |
| 05/18/2007 | CA2627349A1 Azaindole compounds and use thereof as phospholipase-a2 inhibitors |
| 05/18/2007 | CA2627263A1 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
| 05/18/2007 | CA2627260A1 2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl) acetamide derivatives useful in treatment of trpv1 related disorders |
| 05/18/2007 | CA2627114A1 P2x7 receptor antagonists and methods of use |
| 05/18/2007 | CA2627089A1 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
| 05/18/2007 | CA2627086A1 Pharmaceutical salts and polymorphs of n-(5-chl0r0-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide, a factor xa inhibitor |
| 05/18/2007 | CA2627058A1 Anti-misuse microparticulate oral pharmaceutical form |
| 05/18/2007 | CA2627043A1 Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors |
| 05/18/2007 | CA2626961A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
| 05/18/2007 | CA2626898A1 Substituted nicotinamide compounds |
| 05/18/2007 | CA2626897A1 Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
| 05/18/2007 | CA2626846A1 Hydrazone derivatives and uses thereof |
| 05/18/2007 | CA2626734A1 Magnesium-containing polymers for the treatment of hyperphosphatemia |
| 05/18/2007 | CA2626685A1 Benzimidazole derivatives as gyrase inhibitors |
| 05/18/2007 | CA2626682A1 Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
| 05/18/2007 | CA2626483A1 Compounds and compositions as ppar modulators |
| 05/18/2007 | CA2626479A1 Protein kinase inhibitors |
| 05/18/2007 | CA2626446A1 Compounds and compositions as ppar modulators |
| 05/18/2007 | CA2626443A1 Oxazole and thiazole ppar modulators |
| 05/18/2007 | CA2626352A1 Methods and compositions for administration of iron for the treatment of restless leg syndrome |
| 05/18/2007 | CA2626029A1 Pharmaceutical gallium compositions and methods |
| 05/18/2007 | CA2624905A1 Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| 05/18/2007 | CA2624903A1 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| 05/18/2007 | CA2622136A1 Methods of using saha and erlotinib for treating cancer |
| 05/18/2007 | CA2620814A1 Use of at least one compound of the family of the avermectins or of the family of the milbemycins in the treatment of ophthalmic pathologies |
| 05/18/2007 | CA2611889A1 Substituted tetrahydroquinolines |
| 05/18/2007 | CA2608726A1 Inhibitors of vegf receptor and hgf receptor signaling |
| 05/18/2007 | CA2607982A1 Styrylsulfonamides, their manufacture and use as pharmaceutical agents |
| 05/18/2007 | CA2590511A1 Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor |
| 05/18/2007 | CA2537783A1 Tumour treatment |
| 05/17/2007 | US20070112195 metalating a nicotines with lithium teramethylpipridine in presence of trialkyl or aryltin halide to form an intermediate such as 1-methylpyrrolidin-2-yl)-2-tricyclohexylstannanyl)pyridine, halogenating intermediate with I2, Br2 or N-bromosuccinimide; nicotinic acetylcholine receptor modulator |
| 05/17/2007 | US20070112194 Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof |
| 05/17/2007 | US20070112176 Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| 05/17/2007 | US20070112077 2-Methylene-1 alpha ,25-Dihydroxy-des-C,D-19-norvitamin D3; anticarcinogenic, antiinflammatory agent; psoriasis; leukemia; colon, breast, prostate cancer; multiple sclerosis, lupus, diabetes mellitus, host versus graft reaction, rheumatoid arthritis, asthma, eczema, or inflammatory bowel diseases |
| 05/17/2007 | US20070112076 Methods and materials for treating retinopathy |
| 05/17/2007 | US20070112075 Stable pharmaceutical formulations containing escitalopram and bupropion |
| 05/17/2007 | US20070112074 Tramadol recovery process |
| 05/17/2007 | US20070112073 Protriptyline hydrochloride crystalline form |
| 05/17/2007 | US20070112072 cytosine suppressive antiinflammatory agents; viricides; immunomodulators |
| 05/17/2007 | US20070112071 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| 05/17/2007 | US20070112070 2-Ethoxy-3-[3'-(3-heptyl-1-methylureido)biphenyl-4-yl]propanoic acid; cosmetics; dermatology; immunotherapy; lipid metabolism; skin disorders; antiinflammatory agents;antiallergens; antiproliferative agents; psoriasis; eczemia; respiratory systemdisorders; antiarthritic agents; anticarcinogenic agents |
| 05/17/2007 | US20070112067 for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions |
| 05/17/2007 | US20070112066 Remedy |
| 05/17/2007 | US20070112065 Use of l-butylphthalide in the manufacture of medicaments for prevention and treatment of cerebral infarct |
| 05/17/2007 | US20070112064 Nucleic acid antioxidant compositions, methods for obtaining such compositions and formulations thereof |
| 05/17/2007 | US20070112063 e.g. 4-(3-Chlorophenylaminothiocarbonylamino)-3,4-dihydro-2,2-dimethyl-6-fluoro-2H-1-benzopyran; potassium channel activator; relaxant activity on smooth muscle cells; active on the pancreatic endocrine tissue as inhibitors of insulin secretion |
| 05/17/2007 | US20070112062 Use of dialkylketone peroxide as biocidal, sterilizing, antiseptic, disinfecting and anti-parasitic agent |
| 05/17/2007 | US20070112061 Heat- or singlet oxygen-generating agents and cancer treatment compositions comprising organic peroxide or chemiluminescent compound |
| 05/17/2007 | US20070112060 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements |
| 05/17/2007 | US20070112059 Cyanopyrrolidine derivatives |
| 05/17/2007 | US20070112058 Novel prostamides for the treatment of glaucoma and related diseases |
| 05/17/2007 | US20070112057 Polymorphic forms of tegaserod maleate |
| 05/17/2007 | US20070112056 Stable modifications of tegaserod hydrogen maleate |
| 05/17/2007 | US20070112055 Crystalline forms of almotriptan and processes for their preparation |
| 05/17/2007 | US20070112054 Process for the preparation of indoles |
| 05/17/2007 | US20070112053 Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor |
| 05/17/2007 | US20070112052 Methods and compositions for treating headache pain with topical NSAID compositions |
| 05/17/2007 | US20070112051 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| 05/17/2007 | US20070112050 HMGCoA reductase inhibitor combinations and uses thereof |
| 05/17/2007 | US20070112049 nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria |
| 05/17/2007 | US20070112048 Broad Spectrum Antibacterial Compounds |
| 05/17/2007 | US20070112047 e.g. 2-[4-(1-cyclobutylaminoethyl)phenyl]-1H-benzimidazole-4-carboxamide; poly-ADP-ribose polymerase inhibitor; antiinflammatory, anticarcinogenic, antidiabetic, antiischemic agent; neurodegenerative diseases |
| 05/17/2007 | US20070112046 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors |
| 05/17/2007 | US20070112045 Triazole ppar modulators |
| 05/17/2007 | US20070112044 Antitumor, anticancer agents; using a 2-amino-5-phenyl-(1,3,4)thiadiazole compound |
| 05/17/2007 | US20070112043 Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof |
| 05/17/2007 | US20070112042 Topical agent for application to the skin prior to luminous treatment |
| 05/17/2007 | US20070112041 Nicardipine injection composition |
| 05/17/2007 | US20070112040 Amino nicotinate derivatives as glucokinase (GLK) modulators |
| 05/17/2007 | US20070112039 Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride |
| 05/17/2007 | US20070112038 mitogen activated protein kinase inhibitors; used in the treatment of hyperproliferative diseases, such as cancer and inflammation in mammals; Methyl 2-(4-bromo-2-fluorophenylamino)-5-ethyl-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate; synergistic use |
| 05/17/2007 | US20070112037 Pyrazole Derivatives |
| 05/17/2007 | US20070112036 Opioid receptor antagonists |
| 05/17/2007 | US20070112034 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives |
| 05/17/2007 | US20070112033 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions |